Latest Content

Improving outcomes in chronic kidney disease relies on improving patient engagement.

Research shows a sharp rise in bisphenol-attributable metabolic disease since 2000, with annual costs exceeding $250 billion in North America.

Remibrutinib shows rapid and sustained relief for chronic spontaneous urticaria, offering a promising oral treatment option for patients.

Immune-boosting herbs were linked to lower autoantibody rates in patients before dermatomyositis onset, suggesting activation of alternative immune pathways.

The accelerated approval was based on a study that evaluated the efficacy in unresectable or metastatic nonsquamous NSCLC.

Previously treated patients with non–small cell lung cancer (NSCLC) saw durable results with andamertinib 240 mg.

A study links seborrheic dermatitis to multiple epithelial barrier diseases, supporting broader assessment for inflammation and barrier dysfunction.

Caregivers face communication challenges in coordinating patient care for older adults, highlighting the need for improved support and training.

Randomized clinical trials increasingly support mental health apps as scalable, cost-efficient tools for managing depression and anxiety.